FGEN

FibroGen, Inc
Data: 2026-01-07
$9.71
Price
7.65%
Change
$21.9375
52W High
$0.2423
52W Low

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Quick Stats

58.9

AI Score

HOLD

0.95

Volume Ratio

Next Earnings

17

+ve Days (30d)

13

-ve Days (30d)

FGEN Stock Summary

Last updated

FGEN is currently trading at $9.71, positioned below its 200-day moving average of $, suggesting bearish momentum. The stock has a 52-week range of $0.2423 to $21.9375.

Technical Analysis: The 50-day moving average stands at $, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads , suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is , which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates FGEN at 58.9/100 with a HOLD recommendation.

FGEN Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

FGEN Price vs Max Options Open Interest
FGEN Max Change In Options Open Interest

FGEN Options - Sort by Max open Interest (near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

FGEN Daily Out of Money Options - Sort by Max open Interest (near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

FGEN Daily In the Money Options - Sort by Max open Interest (near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

FGEN Most Active Options by Volume(near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

FibroGen, Inc is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

FGEN Moving Averages Analysis

FGEN (FibroGen, Inc) Simple Moving Averages

Moving Averages are last updated

Days MA

FGEN Fundamental Analysis

P/E (Forward) 61.3497
P/E (Trailing) --
Market Cap ($) 36.5 million
Earnings/Share ($) -12.85
Net Proft Margin (%) 25.9887
Dividend/Share ($) --
EPS Estimate Current Year ($) -6.97
EPS Estimate Next Year ($) -11.95
WallStreet Target Price ($) 43
Most Recent Quarter